Related Experiment Video
Updated: Apr 20, 2026
Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
Enhancing stem cell survival in an ischemic heart by CRISPR-dCas9-based gene regulation
Alexander Pan1, Neal L Weintraub1, Yaoliang Tang1
1Vascular Biology Center, Department of Medicine, Medical College of Georgia/Georgia Regents University, 1459 Laney Walker Blvd, Augusta, GA 30912, USA.
Insights
CRISPR/dCas9 technology offers a precise method to enhance stem cell survival for treating heart disease. This approach aims to improve therapeutic outcomes by optimizing gene expression for better stem cell longevity.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Gene Editing Technology
Background:
- Ischemic heart disease remains a leading global cause of mortality.
- Stem cell therapy shows promise for cardiac repair, but limited cell survival post-transplantation is a major hurdle.
- Current gene modification strategies for stem cells have limitations, including potential side effects from constitutive overexpression and lack of endogenous regulatory control.
Purpose of the Study:
- To investigate the potential of the CRISPR/dCas9 system for precise endogenous gene regulation in stem cells.
- To activate the heme oxygenase-1 (HO-1) gene, an anti-inflammatory and anti-apoptotic gene, to an optimal level.
- To enhance transplanted stem cell survival and therapeutic efficacy in ischemic heart disease models.
Main Methods:
- Utilizing the CRISPR/dCas9 system for targeted gene activation of heme oxygenase-1 (HO-1) in stem cells.
- Leveraging single guide chimeric RNAs (sgRNAs) for high specificity and efficiency in gene targeting.
- Employing the genome's endogenous regulatory elements for controlled gene expression.
Main Results:
- The CRISPR/dCas9 system enables efficient and specific gene activation.
- This method allows for the utilization of endogenous regulatory elements, potentially leading to safer gene expression.
- The approach aims to improve stem cell longevity and therapeutic benefits in ischemic conditions.
Conclusions:
- CRISPR/dCas9 offers a controllable and efficient platform for stem cell modification.
- Optimized HO-1 expression via CRISPR/dCas9 can enhance stem cell survival in ischemic myocardium.
- This strategy holds potential for improving the therapeutic efficacy of stem cell transplantation for heart disease.
Abstract:
Ischemic heart disease has remained the number one killer around the world for over the past 20 years. While stem cell therapy has become a promising new frontier to repair the damaged heart, limited stem cell survivability post-transplantation has precluded widespread use of this therapy. Strategies to genetically modify stem cells to activate pro-survival and anti-apoptotic and anti-inflammatory pathways, such as Akt and heme oxygenase-1, have been shown to improve the lifespan of transplanted stem cells within the ischemic myocardium, but constitutive overexpression of these pathways at high levels has been shown to have side effects. Therefore, more specific and controlled gene activation would be necessary. Current techniques used for gene regulation include zinc finger and TALE proteins, but there are still disadvantages to each of these methods, such as ease and cost of use. Also, those methods use synthesized promoters to express synthesized cDNA, which lack regulatory elements, including introns and 3' untranslated regions for microRNA mediated post-transcriptional regulation. A new novel technique, the CRISPR/dCas9 system, was recently developed as a simple and efficient method for endogenous gene regulation. With its use of single guide chimeric RNA's (sgRNA's), this system has been shown to provide a high level of specificity and efficiency. When targeting different loci, past studies have found that the CRISPR/dCas9 system can activate gene expression at varying levels. In addition, this system makes use of the genome's endogenous regulatory elements, such as the aforementioned introns and 3' UTR's, which can help provide a safer method of gene activation. If targeted to a gene promoting cellular survival or decreasing cell death, it could potentially improve stem cell longevity in a more efficient and controllable manner. As a result, our hypothesis is to use the CRISPR/dCas9 system to activate expression of an anti-inflammatory and anti-apoptotic gene, such as heme oxygenase-1 (HO-1), to an optimal level to increase transplanted stem cell survival while also mitigating its cytotoxic effects due to lack of internal regulation, thus prolonging its effects within the ischemic myocardium leading to greater therapeutic benefit.
